Data gathered: November 27
Alternative Data for Ventyx Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 73 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Employee Rating | 20 | Sign up | Sign up | Sign up |
| Google Trends | 12 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 31 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,484 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 85 | Sign up | Sign up | Sign up |
About Ventyx Biosciences
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases.
| Price | $2.65 |
| Target Price | Sign up |
| Volume | 2,030,000 |
| Market Cap | $146M |
| Year Range | $1.72 - $7.35 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
 |
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of “Moderate Buy” from BrokeragesNovember 27 - ETF Daily News |
 |
Ventyx Biosciences CEO Mohan Raju buys $959,889 in stockNovember 25 - Investing.com |
 |
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measuresNovember 16 - Yahoo |
|
Ventyx Biosciences’ (VTYX) “Neutral” Rating Reiterated at HC WainwrightNovember 12 - ETF Daily News |
 |
Ventyx Biosciences Reports Q3 Financial Results and Pipeline ProgressNovember 12 - Yahoo |
 |
Ventyx Biosciences’ (VTYX) Outperform Rating Reaffirmed at OppenheimerNovember 12 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 7.9M | -7.9M | -35M | -39M | -0.500 |
| Q2 '24 | 0 | 7.9M | -7.9M | -32M | -35M | -0.450 |
| Q1 '24 | 0 | 8M | -8.1M | -39M | -41M | -0.620 |
| Q4 '23 | 1.1M | 11M | -11M | -47M | -48M | -0.790 |
| Q3 '23 | 0 | 8.2M | -8.2M | -54M | -58M | -0.920 |
Insider Transactions View All
| Mohan Raju filed to buy 2,175,028 shares at $2. November 25 '24 |
| Mohan Raju filed to buy 1,913,276 shares at $1.8. November 25 '24 |
| Auster Martin filed to sell 24,303 shares at $5.4. April 3 '24 |
| Mohan Raju filed to sell 1,578,250 shares at $5.4. April 3 '24 |
| Nuss John filed to sell 264,998 shares at $5.4. April 3 '24 |
Similar companies
Read more about Ventyx Biosciences (VTYX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Ventyx Biosciences?
The Market Cap of Ventyx Biosciences is $146M.
What is the current stock price of Ventyx Biosciences?
Currently, the price of one share of Ventyx Biosciences stock is $2.65.
How can I analyze the VTYX stock price chart for investment decisions?
The VTYX stock price chart above provides a comprehensive visual representation of Ventyx Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ventyx Biosciences shares. Our platform offers an up-to-date VTYX stock price chart, along with technical data analysis and alternative data insights.
Does VTYX offer dividends to its shareholders?
As of our latest update, Ventyx Biosciences (VTYX) does not offer dividends to its shareholders. Investors interested in Ventyx Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Ventyx Biosciences?
Some of the similar stocks of Ventyx Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.